UA80813C2 - Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation - Google Patents

Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation

Info

Publication number
UA80813C2
UA80813C2 UA20040705897A UA20040705897A UA80813C2 UA 80813 C2 UA80813 C2 UA 80813C2 UA 20040705897 A UA20040705897 A UA 20040705897A UA 20040705897 A UA20040705897 A UA 20040705897A UA 80813 C2 UA80813 C2 UA 80813C2
Authority
UA
Ukraine
Prior art keywords
growth factor
epidermal growth
manufacture
injection composition
pharmaceutical injection
Prior art date
Application number
UA20040705897A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40239814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA80813(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA80813C2 publication Critical patent/UA80813C2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UA20040705897A 2001-12-20 2002-12-04 Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation UA80813C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20010308A CU23043A1 (es) 2001-12-20 2001-12-20 Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
PCT/CU2002/000011 WO2003053458A1 (es) 2001-12-20 2002-12-04 Uso de una composición farmacéutica que contiene factor de crecimiento epidérmico (egf) para la prevención de la amputación del pie diabético

Publications (1)

Publication Number Publication Date
UA80813C2 true UA80813C2 (en) 2007-11-12

Family

ID=40239814

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040705897A UA80813C2 (en) 2001-12-20 2002-12-04 Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation

Country Status (22)

Country Link
US (2) US7465704B2 (xx)
EP (1) EP1466617B1 (xx)
JP (1) JP4808378B2 (xx)
KR (1) KR100795654B1 (xx)
CN (1) CN1306954C (xx)
AR (1) AR037824A1 (xx)
AT (1) ATE422897T1 (xx)
AU (1) AU2002361923B2 (xx)
BR (1) BRPI0215214B8 (xx)
CA (1) CA2470971C (xx)
CU (1) CU23043A1 (xx)
DE (1) DE60231248D1 (xx)
DK (1) DK1466617T3 (xx)
ES (1) ES2322568T3 (xx)
HK (1) HK1077740A1 (xx)
MX (1) MXPA04005831A (xx)
MY (1) MY139214A (xx)
PT (1) PT1466617E (xx)
RU (1) RU2289424C2 (xx)
SI (1) SI1466617T1 (xx)
UA (1) UA80813C2 (xx)
WO (1) WO2003053458A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1077740A1 (en) 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
CU23529A1 (es) * 2005-03-02 2010-06-17 Ct Ingenieria Genetica Biotech Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
CU23388B6 (es) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CU23526B6 (es) * 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
CN101496486B (zh) * 2009-03-13 2011-02-16 新疆巴音郭楞蒙古自治州农业科学研究所 一种蘑菇栽培方法
ES2357601B1 (es) 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
ES2468740B1 (es) 2012-11-13 2015-04-01 Consejo Superior De Investigaciones Científicas (Csic) Apósito para cicatrización de heridas comprometidas
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
CN104173366A (zh) * 2014-09-14 2014-12-03 陈钏黄 一种三磷酸腺苷二钠在制备治疗糖尿病足药物中的应用
MX2016016339A (es) * 2016-12-09 2018-06-08 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V Composicion coadyuvante de un factor de crecimiento y un neuropeptido para acelerar la cicatrizacion de heridas y la repitelizacion de organos.
WO2019006127A1 (en) * 2017-06-28 2019-01-03 Rutgers, The State University Of New Jersey ORGANOIDS DERIVED FROM A SINGLE RENAL CELL
WO2019006113A1 (en) * 2017-06-28 2019-01-03 Rutgers, The State University Of New Jersey ORGANOIDS DERIVED FROM A SINGLE CEREBRAL CELL
CU20190022A7 (es) * 2019-03-18 2020-10-20 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica para el tratamiento de la úlcera del pie diabético
WO2022060178A1 (ko) 2020-09-21 2022-03-24 고려대학교 산학협력단 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
KR102581240B1 (ko) 2020-09-21 2023-09-22 고려대학교 산학협력단 유전자의 특이적 메틸화를 이용하여 당뇨족부궤양 재발 또는 예후를 예측하는 방법
KR20230146379A (ko) 2022-04-12 2023-10-19 고려대학교 산학협력단 마이크로바이옴을 이용하여 당뇨족부궤양 예후를 예측하는 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
IL93996A0 (en) 1989-04-04 1991-01-31 Alcon Lab Inc Pharmaceutical composition containing a liposome
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
CA2038945A1 (en) 1989-08-01 1991-02-02 Norman D. Weiner Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
AU629316B2 (en) 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
CA2097063C (en) * 1990-11-27 2006-08-08 Howard P. Greisler Tissue sealant and growth factor containing compositions that promote accelerated wound healing
CN1160582A (zh) * 1996-12-27 1997-10-01 暨南大学生物工程研究所 含有细胞生长因子的皮肤外用组合物
EP1305040B1 (en) * 2000-07-28 2009-09-09 Christopher J. Murphy Transplant media
HK1077740A1 (en) 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
CN1720989A (zh) 2004-07-15 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种表皮生长因子缓释微球及其制备方法与应用

Also Published As

Publication number Publication date
EP1466617A1 (en) 2004-10-13
HK1077740A1 (en) 2006-02-24
US20050107294A1 (en) 2005-05-19
US20080312139A1 (en) 2008-12-18
BRPI0215214B1 (pt) 2017-05-30
MXPA04005831A (es) 2004-09-13
RU2004122091A (ru) 2005-04-10
US7465704B2 (en) 2008-12-16
BRPI0215214B8 (pt) 2021-05-25
RU2289424C2 (ru) 2006-12-20
CN1620308A (zh) 2005-05-25
JP4808378B2 (ja) 2011-11-02
AR037824A1 (es) 2004-12-09
CN1306954C (zh) 2007-03-28
WO2003053458A1 (es) 2003-07-03
CU23043A1 (es) 2005-05-20
DE60231248D1 (de) 2009-04-02
SI1466617T1 (sl) 2009-08-31
PT1466617E (pt) 2009-05-20
MY139214A (en) 2009-08-28
KR100795654B1 (ko) 2008-01-21
BR0215214A (pt) 2004-12-07
ES2322568T3 (es) 2009-06-23
CA2470971C (en) 2011-02-01
AU2002361923A1 (en) 2003-07-09
AU2002361923B2 (en) 2006-02-02
EP1466617B1 (en) 2009-02-18
JP2005516024A (ja) 2005-06-02
ATE422897T1 (de) 2009-03-15
US7799760B2 (en) 2010-09-21
KR20040094669A (ko) 2004-11-10
DK1466617T3 (da) 2009-06-15
CA2470971A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
UA80813C2 (en) Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
MY143742A (en) Pharmaceutical composition of microspheres for preventing diabetic limb amputation
GB0001309D0 (en) Valve arrangement
RS20090105A (xx) Nove kompozicije lekova bazirane na solima tiotropijuma i solima salmeterola
WO2006117459A3 (fr) Orthese compressive de contention du membre inférieur en forme d'article tricoté de type bas, chaussette ou collant
ES2162393T3 (es) Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica.
HK1116683A1 (en) New pharmaceutical compositions containing hyaluronic acid or its derivatives and collagenase for the topical treatment of wounds, burns and ulcers
IL149176A0 (en) Therapeutic use
MY184122A (en) Use of topical composition containing epidermal growth factor (egf) for diabetic foot amputation prevention
RS30104A (xx) Keratinociti koji se mogu primeniti kao biološki aktivne supstance za lečenje rana
RS50593B (sr) Oktenidinske pastile protiv bolesti zapaljenja usta i ždrela
WO2003073981A3 (en) Novel of cytokine inhibitors
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
GB0020504D0 (en) Therapeutic method
NZ519722A (en) Treatment of diabetic ulcers
EP1051976A3 (en) Use of bisphosphate for the treatment of osteogenesis imperfecta
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
Veroux et al. Efficacy of a novel method of intravenous infusion of the prostaglandin analogue iloprost for the treatment of lower-limb critical ischemia: an open-label, nonrandomized study in two cohorts
EA201000501A1 (ru) Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
Nilsson et al. Good-bye slippage-a new fusion to tackle bandage slippage on the foot